Diagnostics and research stocks with the fastest expected revenue growth
Analysts' consensus revenue for the next four quarters against the last four reported. As of .
- Ranked
- 11
- of 74 diagnostics and research stocks we cover
- Median
- +6.7%
- Highest
- +48.3%
- WAT
- Range
- +4.7% to +48.3%
median +6.7%
+4.7%+48.3%
| # | Company | Expected growth | Revenue growth (TTM) | Forward PE | Market cap |
|---|---|---|---|---|---|
| 1 | WATWaters | +48.3% | +52.5% | 30.4× | $46.4B |
| 2 | GHGuardant Health | +31.1% | +42.7% | n/m | $23.7B |
| 3 | NTRANatera | +15.6% | +37.8% | n/m | $56.2B |
| 4 | DHRDanaher | +8.9% | +5.5% | 25.4× | $162.6B |
| 5 | IDXXIDEXX Laboratories | +7.6% | +12.8% | 42.4× | $52.1B |
| 6 | AAgilent Technologies | +6.7% | +8.6% | 26.8× | $49.6B |
| 7 | ILMNIllumina | +5.6% | +4.9% | 41.5× | $35.7B |
| 8 | IQVIQVIA | +5.5% | +8.2% | 19.0× | $42.5B |
| 9 | LHLabcorp | +5.2% | +6.4% | 18.8× | $28.9B |
| 10 | TMOThermo Fisher Scientific | +5.0% | +8.3% | 25.8× | $256.9B |
| 11 | MTDMettler-Toledo International | +4.7% | +6.9% | 34.6× | $34.2B |
Not ranked: 60 with not a meaningful number. 3 companies whose data behind this number has a caveat are left out until it is checked.
A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.
Expected growth for other groups
Other rankings of diagnostics and research stocks
- Diagnostics and research stocks with the lowest PE ratio
- Diagnostics and research stocks cheapest against their own PE history
- Diagnostics and research stocks with the lowest price to sales ratio
- Diagnostics and research stocks with the lowest EV/EBIT
- Diagnostics and research stocks with the highest free cash flow yield
- Diagnostics and research stocks with the fastest revenue growth
- Diagnostics and research stocks with the fastest earnings growth
- Diagnostics and research stocks with the highest profit margins